Journal Home
Search for

Volume 61, Issue 6, Pages 993-1000 (December 2009)


View previous. 18 of 51 View next.

Clinical, histopathologic, and immunophenotypic features of lymphomatoid papulosis with CD8 predominance in 14 pediatric patients

Aieska de Souza, MD, Michael J. Camilleri, MD, David A. Wada, MD, David L. Appert, MD, Lawrence E. Gibson, MD, Rokea A. el-Azhary, MD, PhDCorresponding Author Informationemail address

Accepted 14 May 2009. published online 06 July 2009.

Background

Lymphomatoid papulosis (LyP) is a cyclic papulonodular eruption that is clinically benign and histologically malignant. Association with hematologic neoplasias has been reported in 5% to 20% of all cases.

Objective

We sought to review the clinical and histopathologic features of LyP in pediatric patients.

Methods

We searched for the records of all patients with a clinical and histopathologic diagnosis of LyP seen at our clinic from January 1991 through April 2008. The cases of pediatric patients (aged < 20 years) were reviewed in detail.

Results

Of 123 patients with LyP identified, 14 (11%) were in the pediatric age group. Most were male (64%); mean age of onset was 12 years. Type A LyP was identified in 12 patients, one patient had type B, and none had type C (type not determined in one case). Ten cases showed CD8 predominance by immunohistochemistry. T-cell intracytoplasmic antigen staining was positive in 3 cases of CD8+ LyP type A and the one case of LyP type B. Lesional T-cell receptor gene rearrangement studies were negative in 9 of 10 patients with LyP type A. The average follow-up time was 5.5 years. Lesions improved with treatment in most cases, and none of the cases were associated with hematologic malignancies.

Limitations

This was a retrospective review.

Conclusions

Among our pediatric patients, we noted a predominance of CD8+ LyP, which does not seem to have an aggressive course. Further longitudinal studies are necessary to evaluate prognostic differences between CD4+ and CD8+ LyP and their biological significance.

Department of Dermatology, Mayo Clinic, Rochester, Minnesota

Corresponding Author InformationReprint requests: Rokea A. el-Azhary, MD, PhD, Department of Dermatology, Mayo Clinic, 200 First St SW, Rochester, MN 55905.

 Funding sources: None.

 Conflicts of interest: None declared.

PII: S0190-9622(09)00616-1

doi:10.1016/j.jaad.2009.05.014


View previous. 18 of 51 View next.